Celsion Announces Enrollment Completion for Pivotal Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer
05 sept. 2018 08h00 HE
|
Celsion CORP
550 Patient Study Designed to Determine if ThermoDox® Can Significantly Prolong the Lives of Patients with Liver Cancer OPTIMA Study’s Hypothesis Independently Confirmed by the National Institutes...